drugset
drugset / Trial / NCT00047710

Study of Combined RHUMAB VEGF and Capecitabine-based Chemoradiation for Patients With Locally Advanced Pancreatic Cancer

NCT00047710 ↗

Phase 1 Completed 48 enrolled M.D. Anderson Cancer Center Genentech, Inc. · collab
NaSingle-groupOpen-labelTreatment

Summary

The goal of this clinical research study is to find the highest safe dose of the drug Bevacizumab that can be given in combination with chemoradiation for the treatment of pancreatic cancer. The effect that this combination treatment has on the tumor will also be studied.

Timeline

Start
2002-09
Primary completion
2006-07
Completion
2006-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Bevacizumab Monoclonal antibody 2.5 mg/kg Intravenous
Background Capecitabine Small molecule 650 mg/m2 Oral

Indications

malignant pancreatic neoplasm